Brinker Capital Investments’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Brinker Capital Investments’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,848	Closed	-$2.17M	–	1766
2023 Q4	$2.17M	Sell	6,848 -306	-4%	-$59.5K	0.03%	589
2023 Q3	$1.21M	Sell	7,154 -1,035	-13%	-$195K	0.01%	840
2023 Q2	$1.78M	Buy	+8,189	New	+$1.75M	0.02%	713
2023 Q1	–	Sell	-6,098	Closed	-$1.2M	–	1668
2022 Q4	$1.2M	Buy	6,098 +1,837	+43%	+$394K	0.02%	671
2022 Q3	$958K	Buy	+4,261	New	+$862K	0.02%	726
2021 Q1	–	Sell	-2,088	Closed	-$212K	–	1291
2020 Q4	$212K	Buy	+2,088	New	+$193K	﹤0.01%	986

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Brinker Capital Investments's KRTX Position: Q1 2024 in Review

Brinker Capital Investments sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 6,848 shares — an estimated $2.17M sold.

Brinker Capital Investments first reported a position in KRTX in Q4 2020 and held it in 6 quarters. The position peaked at $2.17M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Brinker Capital Investments reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Brinker Capital Investments sold 6,848 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.17M.
Brinker Capital Investments first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Brinker Capital Investments's Karuna Therapeutics, Inc. Common Stock position peaked at $2.17M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Brinker Capital Investments's 13F filing for Q1 2024, filed 31 Jul 2025.